A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...

In a year when eradicated diseases are on the uptick in America, how will American children survive RFK Jr.’s vaccine ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

Sponsored communities reduce timelines and increase relevance. Digital engagement allows for rapid study launches and ...

While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...